Key facts
- It has raised $2.9M; the latest was Seed Round ($2.9M) in Jan 2026.
- Notable investors include High-Tech Gründerfonds, Gedad Beteiligungs- Und Verwaltungs, ROI Verwaltungsgesellschaft mit beschränkter Haftung, Technologiegründerfonds Sachsen, Universitätsklinikum Carl Gustav Carus Dresden.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cancilico
- ·The full record, as it builds
Funding rounds
No funding rounds for Cancilico are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cancilico
Developer of an AI-powered diagnostic platform designed to enhance accuracy and efficiency in diagnosing diseases. The company's platform improves accuracy and efficiency in diagnosing diseases like hematological cancers through image analysis, automates the classification and counting of cells in bone marrow samples and address a wide array of challenges in medical research, enabling users to get user-friendly AI technology to identify relevant mutations and target structures for the development of digital biomarkers.
- Sector
- Information Technology
- HQ
- Dresden, Germany
- Founded
- 2023
- Employees
- 10
- Website
- cancilico.com/
- Ownership
- Privately Held (backing)
Cancilico doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cancilico shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cancilico in its N-PORT filings yet. We sweep new filings monthly.